Loading...
•
Sep 30, 2024
Rigel Q3 2024 Earnings Report
Rigel reported positive third-quarter and year-to-date net income, driven by strong revenue growth across its commercial portfolio and the acquisition of GAVRETO.
Key Takeaways
Rigel Pharmaceuticals reported a net income of $12.4 million for the third quarter of 2024, with total revenues of $55.3 million. The company's growth was driven by increased sales of TAVALISSE, REZLIDHIA, and GAVRETO, as well as contract revenue from collaborations.
Total revenues for Q3 2024 were $55.3 million, including $26.3 million from TAVALISSE, $5.5 million from REZLIDHIA, and $7.1 million from GAVRETO.
Net income for Q3 2024 was $12.4 million, or $0.71 per share basic and $0.70 per share diluted.
TAVALISSE sales increased by 8% compared to the same period in 2023.
REZLIDHIA sales increased by 107% compared to the same period in 2023.
Forward Guidance
No specific forward guidance was provided in the press release.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...